Targeting mitochondrial metabolism in acute myeloid leukemia

References

• Warburg O. On the origin of cancer cells. Sci. 1956; 123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012; 21(3):297–308.
   PubMed Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015; 373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Villatoro A, Konieczny J, Cuminetti V, et al. Leukemia stem cell release from the stem cell niche to treat acute myeloid leukemia. Front Cell Dev Biol. 2020; 8:607.
   PubMed Web of Science ®Google Scholar
• Stubbins RJ, Maksakova IA, Sanford DS, et al. Mitochondrial metabolism: powering new directions in acute myeloid leukemia. Leuk Lymphoma. 2021:1–11.
   Web of Science ®Google Scholar
• Farge T, Saland E, de Toni F, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017; 7(7):716–735.
   PubMed Web of Science ®Google Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329–341.
   PubMed Web of Science ®Google Scholar
• Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010; 102(13):932–941.
   PubMedGoogle Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225–234.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483(7390):474–478.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553–567.
   PubMed Web of Science ®Google Scholar
• Fu X, Chin RM, Vergnes L, et al. 2-Hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab. 2015; 22(3):508–515.
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015; 21(2):178–184.
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA Signaling. Cell. 2018; 172(1-2):90–105.e23.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med. 2018; 378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020; 135(7):463–471.
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017; 7(5):478–493.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6):722–731.
   PubMed Web of Science ®Google Scholar
• Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017; 130(6):732–741.
   PubMed Web of Science ®Google Scholar
• Stuart SD, Schauble A, Gupta S, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014; 2(1):4.
   PubMedGoogle Scholar
• Zachar Z, Marecek J, Maturo C, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl)). 2011; 89(11):1137–1148.
   PubMed Web of Science ®Google Scholar
• Egawa Y, Saigo C, Kito Y, et al. Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma. PLoS One. 2018; 13(6):e0198940.
   PubMed Web of Science ®Google Scholar
• Mordhorst BR, Kerns KC, Schauflinger M, et al. Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts. Sci Rep. 2019; 9(1):9417.
   PubMedGoogle Scholar
• Gao L, Xu Z, Huang Z, et al. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling. J Exp Clin Cancer Res. 2020; 39(1):73.
   PubMed Web of Science ®Google Scholar
• Pardee TS, Anderson RG, Pladna KM, et al. A phase I study of CPI-613 in combination with High-Dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Clin Cancer Res. 2018; 24(9):2060–2073.
   PubMed Web of Science ®Google Scholar
• van Gastel N, Spinelli JB, Sharda A, et al. Induction of a timed metabolic collapse to overcome cancer chemoresistance. Cell Metab. 2020; 32(3):391–403.e6.
   PubMed Web of Science ®Google Scholar
• Gregory MA, Nemkov T, Park HJ, et al. Targeting glutamine metabolism and redox state for leukemia therapy. Clin Cancer Res. 2019; 25(13):4079–4090.
   PubMed Web of Science ®Google Scholar
• Jacque N, Ronchetti AM, Larrue C, et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood. 2015; 126(11):1346–1356.
   PubMed Web of Science ®Google Scholar
• Matre P, Velez J, Jacamo R, et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget. 2016; 7(48):79722–79735.
   PubMedGoogle Scholar
• Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393–403.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018; 24(12):1859–1866.
   PubMed Web of Science ®Google Scholar
• Sharon D, Cathelin S, Mirali S, et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019; 11(516):eaax2863. DOI:10.1126/scitranslmed.aax2863.
   PubMed Web of Science ®Google Scholar
• Roca-Portoles A, Rodriguez-Blanco G, Sumpton D, et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 2020; 11(8):616.
   PubMed Web of Science ®Google Scholar
• Jones CL, Stevens BM, D'Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018; 34(5):724–740.e4.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020; 135(24):2137–2145.
   PubMed Web of Science ®Google Scholar
• Fang J, Uchiumi T, Yagi M, et al. Dihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction. Biosci Rep. 2013; 33(2):e00021.
   PubMedGoogle Scholar
• Khutornenko AA, Roudko VV, Chernyak BV, et al. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci U S A. 2010; 107(29):12828–12833.
   PubMed Web of Science ®Google Scholar
• Khutornenko AA, Dalina AA, Chernyak BV, et al. The role of dihydroorotate dehydrogenase in apoptosis induction in response to inhibition of the mitochondrial respiratory chain complex III. Acta Naturae. 2014; 6(1):69–75.
   PubMed Web of Science ®Google Scholar
• Bajzikova M, Kovarova J, Coelho AR, et al. Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells. Cell Metab. 2019; 29(2):399–416.e10.
   PubMed Web of Science ®Google Scholar
• Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016; 167(1):171–186.e15.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Brown TD, Kuhn JG, et al. Phase I clinical and pharmacokinetic trial of brequinar sodium (DuP 785; NSC 368390). Cancer Res. 1989; 49(16):4648–4653.
   PubMed Web of Science ®Google Scholar
• Christian S, Merz C, Evans L, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor Bay 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019; 33(10):2403–2415.
   PubMed Web of Science ®Google Scholar
• Molina JR, Sun Y, Protopopova M, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018; 24(7) :1036–1046.
   PubMed Web of Science ®Google Scholar
• Panina SB, Pei J, Baran N, et al. Utilizing synergistic potential of mitochondria-targeting drugs for. Front Oncol. 2020; 10:435.
   PubMed Web of Science ®Google Scholar
• Vangapandu HV, Alston B, Morse J, et al. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget. 2018; 9(38):24980–24991.
   PubMedGoogle Scholar
• Nagasawa J, Mizokami A, Koshida K, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006; 13(5):587–592.
   PubMed Web of Science ®Google Scholar
• Baccelli I, Gareau Y, Lehnertz B, et al. Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell. 2019; 36(1):84–99.e8.
   PubMed Web of Science ®Google Scholar
• Carter JL, Hege K, Kalpage HA, et al. Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. Biochem Pharmacol. 2020; 182:114253.
   PubMed Web of Science ®Google Scholar